Evolving treatment strategies for myeloma

被引：14

作者：

Morgan, GJ

Davies, FE

机构：

[1] Royal Marsden Hosp, Sutton SM2 5PT, Surrey, England

[2] Inst Canc Res, Sutton SM2 5PT, Surrey, England

来源：

BRITISH JOURNAL OF CANCER | 2005年 / 92卷 / 02期

关键词：

myeloma; novel treatments; thalidomide; ImiDs; proteasome inhibitors; targeted treatment;

D O I：

10.1038/sj.bjc.6602341

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this article, we will discuss how treatment strategies for myeloma have evolved and outline the challenges now faced following the introduction of a number of novel active agents. In particular, we will focus on how achieving a maximum response and maintaining such responses is becoming a key therapeutic strategy and how novel agents can be used to achieve this in the context of current strategies such as autologous transplantation.

引用

页码：217 / 221

页数：5

共 35 条

[1] The proteasome: A suitable antineoplastic target [J].

Adams, J .

NATURE REVIEWS CANCER, 2004, 4 (05) :349-360

[2]

[Anonymous], 1998, J Clin Oncol, V16, P3832

[3] A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Stoppa, AM ;

Sotto, JJ ;

Fuzibet, JG ;

Rossi, JF ;

Casassus, P ;

Maisonneuve, H ;

Facon, T ;

Ifrah, N ;

Payen, C ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97

[4] Total therapy with tandem transplants for newly diagnosed multiple myeloma [J].

Barlogie, B ;

Jagannath, S ;

Desikan, KR ;

Mattox, S ;

Vesole, D ;

Siegel, D ;

Tricot, G ;

Munshi, N ;

Fassas, A ;

Singhal, S ;

Mehta, J ;

Anaissie, E ;

Dhodapkar, D ;

Naucke, S ;

Cromer, J ;

Sawyer, J ;

Epstein, J ;

Spoon, D ;

Ayers, D ;

Cheson, B ;

Crowley, J .

BLOOD, 1999, 93 (01) :55-65

[5] Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients [J].

Berenson, JR ;

Crowley, JJ ;

Grogan, TM ;

Zangmeister, J ;

Briggs, AD ;

Mills, GM ;

Barlogie, B ;

Salmon, SE .

BLOOD, 2002, 99 (09) :3163-3168

[6]

Casassus P, 2001, BRIT J HAEMATOL, V113, P1020

[7] Thalidomide in multiple myeloma: Current status and future prospects [J].

Cavenagh, JD ;

Oakervee, H .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (01) :18-26

[8] High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma [J].

Child, JA ;

Morgan, GJ ;

Davies, FE ;

Owen, RG ;

Bell, SE ;

Hawkins, K ;

Brown, J ;

Drayson, MT ;

Selby, PJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (19) :1875-1883

[9] Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [J].

Davies, FE ;

Raje, N ;

Hideshima, T ;

Lentzsch, S ;

Young, G ;

Tai, YT ;

Lin, B ;

Podar, K ;

Gupta, D ;

Chauhan, D ;

Treon, SP ;

Richardson, PG ;

Schlossman, RL ;

Morgan, GJ ;

Muller, GW ;

Stirling, DI ;

Anderson, KC .

BLOOD, 2001, 98 (01) :210-216

[10] The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma [J].

Davies, FE ;

Forsyth, PD ;

Rawstron, AC ;

Owen, RG ;

Pratt, G ;

Evans, PAS ;

Richards, SJ ;

Drayson, M ;

Smith, GM ;

Selby, PJ ;

Child, JA ;

Morgan, GJ .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (03) :814-819

← 1 2 3 4 →